An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy

Clinical trial NCT01830972 · COMPLETED

Trial details

NCT number: NCT01830972
Sponsor: Ultragenyx Pharmaceutical Inc
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

GNE Myopathy Hereditary Inclusion Body Myopathy (HIBM)

Start date: 2013-06-04
Primary completion: 2017-02-14
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.